AIBNi009-A

Extracted from hPSCreg

GENIE 49

Details

Tissue & Disease as reported

Biopsy Location
Ontology ID: fma9670
Label: Portion of blood
Definition: Portion of body substance which has as its parts plasma and blood cells.
Tissue for derived iPSC
Disease as reported (Donor)
Epilepsy

Genetic Information

No genetic information available for this cell line

Associated Publications

Journal Year Article
Stem cell research 2022 Human induced pluripotent stem cells generated from epilepsy patients for use as in vitro models for drug screening
Stem Cell Research 2022 Human induced pluripotent stem cells generated from epilepsy patients for use as in vitro models for drug screening.

Line Custodianship

Cell Line Maintainer

Wolvetang-AIBN

View all cell lines from this group

Cell Line Producer

Australian Institute for Bioengineering and Nanotechnology

Affiliated Institutions
  • Australian Institute for Bioengineering and Nanotechnology, Brisbane, Australia

Source

Donor Derived

Age: 25-29

Biological Sex: Male

Disease: MONDO:0005027
Label: epilepsy
Definition: A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.

Derivation Details

Induced Pluripotent Cell Derivation Details

Source Cell Type: CL:2000001
Label: peripheral blood mononuclear cell
Definition: A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.

Source Cell Origin: UBERON:0000178
Label: blood
Definition: A fluid that is composed of blood plasma and erythrocytes.

Derivation Year: 2020

Reprogramming Method

Vector Type: Not integrated

Vector: Sendai Virus

Kit: [kit] CytoTune-iPS 2.0 Sendai reprogramming kit

Detected: {{ details.non_integrated_vector.get_detected_reprogramming_vector_display }}

Ethics

Ethics Number: QRBW/54086

Institution Human Research Ethics Council: The University of Queensland Human Ethics Research Office

Approval Date: Jan. 1, 2019

Modifications

No genomic modifications available for this line.

Quality Assurance

Genomic Characterisation

Passage Number: 15

Karyotype: 46,XY

Karyotype Method: G-banding

Summary: Karyotyping occurred from passage 15 at a resolution of 500bphs. Ten metaphase spreads were analysed.

STR analysis Results:

Performed but not available.

Microbiology and Virology Screening

Disease Result
HIV 1 Negative
HIV 2 Negative
HEP B Negative
HEP C Negative
Mycoplasma Negative

Characterisation of Undifferentiated Cells

Marker Method
NANOG Immunostaining
OCT4 Immunostaining
SOX2 Immunostaining
TRA-1-60 Immunostaining
TRA-1-81 Immunostaining

Scorecard Results

Undifferentiated Cells

No available data for this cell line.

Pluripotency

No available data for this cell line.

Pluripotency Characterisation

Endoderm

In vitro directed differentiation

Assessed by: RT-qPCR

Markers: FOXA2; SOX17

Mesoderm

In vitro directed differentiation

Assessed by: RT-qPCR

Markers: HAND1; PDGFRA

Ectoderm

In vitro directed differentiation

Assessed by: RT-qPCR

Markers: NR2F2; PAX6

Growth Characteristics

Culture Medium and Growth Conditions

CO2 concentration: 5%

O2 concentration: Unavailable

Medium Items:

  • Base Medium: mTeSR Plus - STEMCELL Technologies
  • Base Coat: Matrigel (hESC Qualified) - Corning

Passage Method: Enzyme-free cell dissociation